<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>Monoclonal antibodies directed against two human B cell-restricted antigens, CD19 and CD22, were conjugated to highly purified ricin A chain </plain></SENT>
<SENT sid="1" pm="."><plain>These A chain immunotoxins (A-IT) were specifically cytotoxic to Daudi cells and <z:mpath ids='MPATH_458'>normal</z:mpath> human peripheral blood B cells in vitro </plain></SENT>
<SENT sid="2" pm="."><plain>The concentration required for 50% inhibition of protein synthesis (IC50) in these cells ranged from 7.5 X 10(-10) M to 4.2 X 10(-9) M </plain></SENT>
<SENT sid="3" pm="."><plain>The specific toxicities of these A-ITs for Daudi cells were augmented 2- to 6-fold in the presence of 20mM <z:chebi fb="0" ids="31206">NH4Cl</z:chebi> </plain></SENT>
<SENT sid="4" pm="."><plain>These studies demonstrate that A-ITs specific for CD19 and CD22 may be useful in the clinical treatment of B cell <z:e sem="disease" ids="C0006826" disease_type="Neoplastic Process" abbrv="">malignancies</z:e> </plain></SENT>
</text></document>